Moderna, Inc. (MRNA)
Shareholders of Moderna, Inc. Should Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights - MRNA
NEW YORK, NY / ACCESSWIRE / August 26, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)
Moderna, Inc.'s combination flu and COVID-19 vaccine, mRNA-1083, showed strong Phase 3 results in adults over 50. Pfizer/BioNTech's combination vaccine faced setbacks, giving Moderna a potential advantage in the market. The market for Moderna's RSV vaccine may be limited due to updated CDC recommendations.
Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights – MRNA
NEW YORK, NY / ACCESSWIRE / August 26, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors who lost money on Moderna, Inc.(MRNA) should contact Levi & Korsinsky about pending Class Action - MRNA
NEW YORK, NY / ACCESSWIRE / August 26, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Encourages Investors To Join A Case For Securities Fraud Against Moderna Inc
LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.
Contact Levi & Korsinsky by October 8, 2024 Deadline to Join Class Action Against Moderna, Inc.(MRNA)
NEW YORK, NY / ACCESSWIRE / August 26, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").
Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNA
NEW YORK, NY / ACCESSWIRE / August 25, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors in Moderna, Inc. Should Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights - MRNA
NEW YORK, NY / ACCESSWIRE / August 25, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna Inc Is Being Sued For Possible Securities Law Violations And Shareholders With Losses Are Invited To Participate
LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 8, 2024 in Moderna Lawsuit - MRNA
NEW YORK, NY / ACCESSWIRE / August 25, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
MRNA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / August 25, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").
